Answers are grounded in this paper and cite their sources.
Meta-analysis identifies low nutritional indices as predictors of overall survival in gastric cancer, suggesting tailored interventions.
Gastric cancer (GC), the fifth leading cause of global cancer mortality, imposes significant clinical and economic burdens, particularly in high-incidence regions such as East Asia. Despite advancements in treatment, postoperative complications persist in 12.8-14% of patients, with malnutrition being a critical risk factor. Geographic variations in treatment paradigms (e.g., predominant neoadjuvant therapy in the West vs. upfront surgery in East Asia for selected stage III) necessitate region-specific prognostic analyses of the same. This study evaluated the prognostic role of preoperative nutritional indices, the Prognostic Nutritional Index (PNI) and Nutritional Risk Screening 2002 (NRS-2002), using a dual approach: a meta-analysis of 27 global cohorts (2016-2023, n=19,285 patients) and a retrospective cohort study (n = 203 patients, 2021-2024). Pooled meta-analysis revealed that low preoperative PNI was significantly correlated with reduced overall survival (OS: multifactorial study HR = 1.344, 95% CI = 1.111-1.625, P < 0.001; univariate study HR = 3.140, 95% CI = 1.564-6.302) and disease-free survival (DFS: multifactorial study HR = 0.977, 95% CI = 0.667-1.432, P < 0.001; univariate study HR = 2.890, 95% CI = 2.236-3.735, P = 0.185), alongside increased risks of infectious complications (RR = 0.665, 95% CI = 0.544-0.814, P < 0.001). Retrospective data demonstrated that the combined PNI and NRS-2002 assessment improved the predictive accuracy for early postoperative complications (AUC=0.657 vs. 0.541 for PNI alone). Patients with complications experienced prolonged hospitalization (Δ = 6.31 days, P < 0.001) and higher costs. Multivariate analysis identified low PNI (OR = 2.24) and high NRS-2002 (OR = 2.49) as independent predictors of adverse outcomes. These findings underscore the necessity of integrating preoperative nutritional screening into clinical protocols to stratify high-risk patients, guide targeted interventions, and mitigate the economic burden associated with postoperative morbidity. Our multidimensional model highlights the synergistic value of combining immunonutritional biomarkers with conventional risk tools, offering a translatable framework for optimizing perioperative care in GC. While our findings reflect gastric cancer management in high-incidence regions, validation in Western cohorts undergoing neoadjuvant therapy is required.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: